Praxsyn(OTC) PXYN

Market Cap$600.00

Since IPO (2010)-100%

5 Year-99%

1 Year+0%

1 Month+0%

$0.00

+0.00%

+0.00Today

Praxsyn last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-07-22

Praxsyn stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-06-03
1 month	+0%	USD 0.00	2026-06-03
3 month	+0%	USD 0.00	2026-03-23
Year to date	+0%	USD 0.00	2025-12-29
1 year	+0%	USD 0.00	2025-07-15
3 year	+0%	USD 0.00	2023-07-05
5 year	-99%	USD 0.00	2021-07-20
Since inception	-100%	USD 2.89	2010-08-16

Praxsyn Financials at a Glance

Market Cap

$600.00

Revenue (TTM)

$20.47M

Net Income (TTM)

$2.68M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

8.46 (High)

Dividend

$0.00

Beta (Volatility)

8.46 (High)

Price

$0.00

Volume

92,600

Open

$0.00

Price

$0.00

Volume

92,600

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

8.46 (High)

Price

$0.00

Volume

92,600

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

PXYN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Praxsyn

Praxsyn Corporation operates as a healthcare enterprise, supplying medical professionals with specific medications and related services for their patients. The company specializes in creating non-narcotic and non-habit-forming treatments, utilizing therapeutic and preventative compounds.

Products and Services

Non-narcotic medications for pain management
Transdermal creams and patches for various conditions
Oral capsules targeting erectile dysfunction and metabolic disorders

Growth Outlook

Recent revenue of $41,926 indicates potential for recovery
Focus on California's workers' compensation program expands market reach
Innovative product development may attract new partnerships

Financial Highlights

Trailing twelve months (TTM) revenue of $41,926 shows growth potential
Current ratio of 1.28 suggests adequate short-term financial health
Net income margin of -6.95% indicates room for operational improvement

Praxsyn Corporation is positioned within the medical and pharmaceutical industry, focusing on innovative healthcare solutions. The company has a diverse product line that addresses various medical needs, particularly in pain management and metabolic disorders. Recent financial data indicates a revenue of $41,926, which, while modest, reflects a potential upward trend as the company continues to develop its offerings. The growth outlook appears promising, especially with the focus on California's workers' compensation program, which could enhance market penetration. Additionally, the company's commitment to non-narcotic treatments aligns with current healthcare trends favoring safer alternatives. Financially, the current ratio of 1.28 suggests that Praxsyn Corporation maintains a healthy balance between its current assets and liabilities, providing a cushion for operational expenses. However, the negative net income margin highlights the need for strategic improvements in cost management and revenue generation. Overall, Praxsyn Corporation presents an intriguing opportunity for investors interested in the evolving healthcare landscape.

AI Generated • Jul 10, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Las Vegas, NV 89101, US

PXYN Financials

Key Financial Metrics (TTM)

Gross Margin

29.39%

Operating Margin

-240.85%

Net Income Margin

-695.52%

Return on Equity

-20.21%

Return on Capital

-4.71%

Return on Assets

-5.08%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$600.00

Shares Outstanding

634.67M

Volume

92.60K

Avg. Volume

3.65K

Financials (TTM)

Gross Profit

$17.53M

Operating Income

$5.15M

EBITDA

$5.17M

Operating Cash Flow

-$10.81M

Capital Expenditure

-$288.16K

Free Cash Flow

-$11.10M

Cash & ST Invst.

$289.64K

Total Debt

$2.10M

Praxsyn Performance Analysis

Praxsyn sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2015-09-30	15.8%
Q1	2019-03-31	N/A
Q2	2019-06-30	N/A
Q3	2019-09-30	N/A

Praxsyn sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2015-09-30	-8.7%
Q1	2019-03-31	N/A
Q2	2019-06-30	-107.8%
Q3	2019-09-30	-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q3 2019YOY CHG

Revenue

$41.93K

-99.8%

Gross Profit

$24.46K

-99.8%

Gross Margin

58.33%

N/A

Market Cap

$600.00

N/A

Market Cap/Employee

$9.09

N/A

Employees

N/A

Net Income

-$142.00K

-104.5%

EBITDA

-$117.00K

-102.1%

Quarterly Fundamentals

Name

Q3 2019YOY CHG

Total Cash

$289.64K

-94.0%

Total Debt

$2.10M

-41.7%

Accounts Receivable

$11.06M

+54.5%

Inventory

$0.00

-100.0%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$2.10M

-38.4%

Return on Assets

-5.08%

N/A

Return on Invested Capital

-7.78%

N/A

Free Cash Flow

-$5.90M

+14.6%

Operating Cash Flow

-$5.77M

+16.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IPAHInterpharm Holdings, Inc.

IPAHInterpharm Holdings, Inc.$0.00+0.00%

RBIIRising Biosciences, Inc.

RBIIRising Biosciences, Inc.$0.00+0.00%

MHTXManhattan Scientifics, Inc.

MHTXManhattan Scientifics, Inc.$0.00+0.00%

DNAGDNAPrint Genomics, Inc.

DNAGDNAPrint Genomics, Inc.$0.00+0.00%

SPPHSpencer Pharmaceutical Inc.

SPPHSpencer Pharmaceutical Inc.$0.00+0.00%

USRMU.S. Stem Cell, Inc.

USRMU.S. Stem Cell, Inc.$0.00+0.00%

JNHMFJack Nathan Medical Corp.

JNHMFJack Nathan Medical Corp.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PLTRPalantir Technologies

PLTRPalantir Technologies$162.66+0.29%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$125.33+0.09%

NVDANvidia

NVDANvidia$211.94+0.03%

INTCIntel

INTCIntel$100.86+0.11%

AMIXAutonomix Medical

AMIXAutonomix Medical$19.50+4.34%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.07+0.03%

NOKNokia

NOKNokia$9.92+0.06%

Questions About PXYN

What is the current price of Praxsyn?

Praxsyn is trading at $0.00 per share.

What is the 52-week range for Praxsyn?

Over the past 52 weeks, Praxsyn has traded between $0.00 and $0.00.

How much debt does Praxsyn have?

Praxsyn total debt is unavailable.

How much cash does Praxsyn have on hand?

Praxsyn does not have cash on hand data available.

What is Praxsyn’s dividend yield?

Praxsyn does not currently have a dividend yield.

Praxsyn(OTC) PXYN

Praxsyn Financials at a Glance

PXYN News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Praxsyn

PXYN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Praxsyn Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PXYN

What is the current price of Praxsyn?

What is the 52-week range for Praxsyn?

How much debt does Praxsyn have?

How much cash does Praxsyn have on hand?

What is Praxsyn’s dividend yield?

Premium Investing Services